Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]
Phyllis H Niolon, Ph.D. [clinicaltrials_resource:0885c1cd8e27e14c4db5ad7153aa12b3]Scott Dowell, MD [clinicaltrials_resource:09a2cc622a7c3345569686ff955bec76]Dawn K Smith, MD, MS, MPH [clinicaltrials_resource:0a1ec26d47c5085b8776b8c67257304f]Dawn K Smith, MD, MS, MPH [clinicaltrials_resource:0dc43984dd8e1585d924aff793eb201a]Meghna Desai, PhD MPH [clinicaltrials_resource:0e419d2169185b60579b7759fd3820d5]Kevin Griffith, MD, MPH [clinicaltrials_resource:0e6f9359579516b9198905d2c19b9041]Sherry L Farr, PhD [clinicaltrials_resource:0ff24d876bd4b5f20915c375966f5dec]Alexandre Macedo de Oliveira, MD [clinicaltrials_resource:12318605bd2c618adcf4810145098154]Pamela Bachanas, PhD [clinicaltrials_resource:14a6868208d11f78cc69c943fc122070]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Meghna Desai, PhD [clinicaltrials_resource:16246aa8763a5df11bb01fb9fc5688c9]Alexandre Macedo de Oliveira, MD [clinicaltrials_resource:1834138843d9fc06172dc94039e0e8f5]Kim S Miller, PhD [clinicaltrials_resource:190396a6c9efc57e8cd8318ccd0f5ab6]Kevin S. Griffith, MD, MPH [clinicaltrials_resource:195a56dfd7795f474a80a35dcaf46c43]Paul Mehta, MD [clinicaltrials_resource:1a34cab63d4edbd9d575a4c7a19d3548]Kevin S. Griffith, MD, MPH [clinicaltrials_resource:1b55c7010af538ca41afe6ad553a0a05]John E Gimnig, Ph.D. [clinicaltrials_resource:1c4db6a377d60670b3a545da08afdc52]Rachel N Bronzan, MD, MPH [clinicaltrials_resource:1ce48052fdaa617392f889833bc8f6b9]Jacek Skarbinski, MD [clinicaltrials_resource:1e684db6b9f2f3c700d06a3636f9431b]Louise Causer, MBBS, MScPH [clinicaltrials_resource:1fb81c251fbb3dce49c3a72dfd5b1abd]Eric Mintz, MD, MPH [clinicaltrials_resource:217666a7a01f079728457d05e5cd5204]Tom Oluoch, MSc [clinicaltrials_resource:23307c6006e0fd1d79bbed06a23fc0b9]Robert D. Newman, MD, MPH [clinicaltrials_resource:254a2aca231241bb878496031cf17b1d]Robin MacGowan, MPH [clinicaltrials_resource:28cb9e4e2d453808d57c0af6bd4f86c6]Kevin S. Griffith, MD, MPH [clinicaltrials_resource:29317a0fcd7d192e9acf6ec81d7c754c]Paul Mehta, MD [clinicaltrials_resource:29a3bea183fc5c919f686001182d623a]Denise Garrett, MD [clinicaltrials_resource:2c195491e4213da9e516dee6adfe4d8a]Jennifer M Hootman, PhD [clinicaltrials_resource:2c51b731d5765c59bedb4d05e012469d]Paul Mehta, MD [clinicaltrials_resource:2d94080372d093fe29f818fd68f8738b]Robin MacGowan, MPH [clinicaltrials_resource:2f2e09311ef243b4b8663737dea548da]Fatimah S Dawood, MD [clinicaltrials_resource:31f43e869a3f59cf78b902e7389746ad]Peter B Bloland, DVM, MPVM [clinicaltrials_resource:32eba1e90fbfcf914b6d8a5a2f2cf812]Michael D Green, PhD [clinicaltrials_resource:33ce5ff9841c8b591a4075d1f2f7ce2d]Seema Jain, MD [clinicaltrials_resource:3507a95a8aa4b455c364cef2ce268437]Kevin S. Griffith, MD, MPH [clinicaltrials_resource:364cf6d3e821a2190dc8f063f81cd764]Rosa L Floyd, DSN [clinicaltrials_resource:370881ee4ed50d0e84a066a6c7156779]Ruth Perou, PhD [clinicaltrials_resource:3c146a766d7f89a0c863eb98d925b6ad]Daniel P Kidder, PhD [clinicaltrials_resource:3c3aad51dc02b6a551b137f0e3bd6229]Susan P Danner, BA [clinicaltrials_resource:403d902802dd6bd7fa7dcbe32700e0c2]Kevin S. Griffith, MD, MPH [clinicaltrials_resource:404131e569cdffc29ceecf2960478e48]
affiliation [clinicaltrials_vocabulary:affiliation]
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis [clinicaltrials:NCT00023335]TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB [clinicaltrials:NCT00023348]TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen [clinicaltrials:NCT00023361]clinicaltrials:NCT00023374TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine [clinicaltrials:NCT00023387]TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB [clinicaltrials:NCT00023400]TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz [clinicaltrials:NCT00023413]TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis [clinicaltrials:NCT00023426]TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment [clinicaltrials:NCT00023439]clinicaltrials:NCT00023452Botswana Tenofovir Oral HIV Prophylaxis Trial [clinicaltrials:NCT00111150]Intermittent Preventive Treatment With Antimalarials in Kenyan Infants [clinicaltrials:NCT00111163]CDC Anthrax Vaccine Clinical Trial [clinicaltrials:NCT00119067]Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage [clinicaltrials:NCT00119080]Home-based AIDS Care Project [clinicaltrials:NCT00119093]clinicaltrials:NCT00119106Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi [clinicaltrials:NCT00126906]Chlorproguanil-Dapsone in Pregnant Women [clinicaltrials:NCT00126971]Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness [clinicaltrials:NCT00127504]Antimalarial Drug Resistance in Mali [clinicaltrials:NCT00127998]Treatment and Diagnosis of Plague [clinicaltrials:NCT00128466]The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya [clinicaltrials:NCT00130065]clinicaltrials:NCT00131677CHOICE: Communicating Health Options Through Information and Cancer Education [clinicaltrials:NCT00134589]Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children [clinicaltrials:NCT00134602]Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools [clinicaltrials:NCT00136279]clinicaltrials:NCT00136370Promoting Colorectal Cancer Screening in Rural Colorado [clinicaltrials:NCT00137592]Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening [clinicaltrials:NCT00137618]clinicaltrials:NCT00137631Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents [clinicaltrials:NCT00137644]Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance [clinicaltrials:NCT00137657]Colorectal Cancer Control in Appalachian Churches [clinicaltrials:NCT00137683]Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine [clinicaltrials:NCT00137696]Parents Matter!: Interventions to Promote Effective Parent-Child Communication [clinicaltrials:NCT00137943]Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area [clinicaltrials:NCT00139100]clinicaltrials:NCT00139113Research to Improve Smoke Alarm Functioning and Maintenance [clinicaltrials:NCT00139126]A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A [clinicaltrials:NCT00139139]Using the Healthcare Visit to Improve Contraceptive Use [clinicaltrials:NCT00140296]
collaborator [clinicaltrials_vocabulary:collaborator]
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis [clinicaltrials:NCT00023335]TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB [clinicaltrials:NCT00023348]TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen [clinicaltrials:NCT00023361]clinicaltrials:NCT00023374TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine [clinicaltrials:NCT00023387]TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB [clinicaltrials:NCT00023400]TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz [clinicaltrials:NCT00023413]TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis [clinicaltrials:NCT00023426]TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment [clinicaltrials:NCT00023439]clinicaltrials:NCT00023452Botswana Tenofovir Oral HIV Prophylaxis Trial [clinicaltrials:NCT00111150]Intermittent Preventive Treatment With Antimalarials in Kenyan Infants [clinicaltrials:NCT00111163]Treatment and Management of Women With Bleeding Disorders [clinicaltrials:NCT00111215]CDC Anthrax Vaccine Clinical Trial [clinicaltrials:NCT00119067]Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage [clinicaltrials:NCT00119080]Home-based AIDS Care Project [clinicaltrials:NCT00119093]clinicaltrials:NCT00119106Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi [clinicaltrials:NCT00126906]Chlorproguanil-Dapsone in Pregnant Women [clinicaltrials:NCT00126971]Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness [clinicaltrials:NCT00127504]Antimalarial Drug Resistance in Mali [clinicaltrials:NCT00127998]Treatment and Diagnosis of Plague [clinicaltrials:NCT00128466]The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya [clinicaltrials:NCT00130065]clinicaltrials:NCT00131677Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection [clinicaltrials:NCT00132457]Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality [clinicaltrials:NCT00133744]CHOICE: Communicating Health Options Through Information and Cancer Education [clinicaltrials:NCT00134589]Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children [clinicaltrials:NCT00134602]Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women [clinicaltrials:NCT00136227]Adherence With Iron Sprinkles Among High-Risk Infants [clinicaltrials:NCT00136266]Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools [clinicaltrials:NCT00136279]clinicaltrials:NCT00136370Promoting Colorectal Cancer Screening in Rural Colorado [clinicaltrials:NCT00137592]Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening [clinicaltrials:NCT00137618]clinicaltrials:NCT00137631Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents [clinicaltrials:NCT00137644]Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance [clinicaltrials:NCT00137657]Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients [clinicaltrials:NCT00137670]Colorectal Cancer Control in Appalachian Churches [clinicaltrials:NCT00137683]Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine [clinicaltrials:NCT00137696]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Daniel Kidder, Behavioral Scientist, Centers for Disease Control and Prevention [clinicaltrials_resource:060f35e6df493217b739d3439decceea]Vicki Benard, Ph.D., Project Officer, Centers for Disease Control and Prevention [clinicaltrials_resource:2d1773e69cabd42dbd3163de2b85e2df]Anna Bowen, Centers for Disease Control and Prevention [clinicaltrials_resource:51f4658285a99a597229c9030265de13]Michael Thigpen, Medical Officer, Centers for Disease Control and Prevention [clinicaltrials_resource:8aa9afe9121377b114d239b6d9405f9d]Jennifer Galbraith/ Behavioral Scientist, Centers for Disease Control and Prevention [clinicaltrials_resource:eaf6e7dd83aee6bce27219a5b27437f8]
organization [clinicaltrials_vocabulary:organization]
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis [clinicaltrials:NCT00023335]TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB [clinicaltrials:NCT00023348]TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen [clinicaltrials:NCT00023361]clinicaltrials:NCT00023374TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine [clinicaltrials:NCT00023387]TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB [clinicaltrials:NCT00023400]TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz [clinicaltrials:NCT00023413]TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis [clinicaltrials:NCT00023426]TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment [clinicaltrials:NCT00023439]clinicaltrials:NCT00023452Botswana Tenofovir Oral HIV Prophylaxis Trial [clinicaltrials:NCT00111150]Intermittent Preventive Treatment With Antimalarials in Kenyan Infants [clinicaltrials:NCT00111163]Treatment and Management of Women With Bleeding Disorders [clinicaltrials:NCT00111215]CDC Anthrax Vaccine Clinical Trial [clinicaltrials:NCT00119067]Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage [clinicaltrials:NCT00119080]Home-based AIDS Care Project [clinicaltrials:NCT00119093]clinicaltrials:NCT00119106Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi [clinicaltrials:NCT00126906]Chlorproguanil-Dapsone in Pregnant Women [clinicaltrials:NCT00126971]Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness [clinicaltrials:NCT00127504]Antimalarial Drug Resistance in Mali [clinicaltrials:NCT00127998]Treatment and Diagnosis of Plague [clinicaltrials:NCT00128466]The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya [clinicaltrials:NCT00130065]clinicaltrials:NCT00131677Study of UC-781 Vaginal Microbicide [clinicaltrials:NCT00132444]Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection [clinicaltrials:NCT00132457]Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality [clinicaltrials:NCT00133744]CHOICE: Communicating Health Options Through Information and Cancer Education [clinicaltrials:NCT00134589]Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children [clinicaltrials:NCT00134602]Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women [clinicaltrials:NCT00136227]Adherence With Iron Sprinkles Among High-Risk Infants [clinicaltrials:NCT00136266]Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools [clinicaltrials:NCT00136279]clinicaltrials:NCT00136370Promoting Colorectal Cancer Screening in Rural Colorado [clinicaltrials:NCT00137592]Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening [clinicaltrials:NCT00137618]clinicaltrials:NCT00137631Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents [clinicaltrials:NCT00137644]Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance [clinicaltrials:NCT00137657]Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients [clinicaltrials:NCT00137670]Colorectal Cancer Control in Appalachian Churches [clinicaltrials:NCT00137683]
source [clinicaltrials_vocabulary:source]
Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]
Bio2RDF identifier
9bf9dd4a92652d24bc69b64f4927b75f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f
title
Centers for Disease Control and Prevention
@en
type
label
Centers for Disease Control an ...... 9dd4a92652d24bc69b64f4927b75f]
@en